Primary nodal peripheral T-cell lymphomas: diagnosis and therapeutic considerations

Luis Alberto de Pádua Covas Lage, Tamara Carvalho Dos Santos Cabral, Renata de Oliveira Costa, Marianne de Castro Gonçalves, Debora Levy, Maria Cláudia Nogueira Zerbini, Juliana Pereira, Luis Alberto de Pádua Covas Lage, Tamara Carvalho Dos Santos Cabral, Renata de Oliveira Costa, Marianne de Castro Gonçalves, Debora Levy, Maria Cláudia Nogueira Zerbini, Juliana Pereira

Abstract

Nodal peripheral T-cell lymphomas are a rare group of neoplasms derived from post-thymic and activated T lymphocytes. A review of scientific articles listed in PubMed, Lilacs, and the Cochrane Library databases was performed using the term "peripheral T-cell lymphomas". According to the World Health Organization classification of hematopoietic tissue tumors, this group of neoplasms consists of peripheral T-cell lymphoma not otherwise specified (PTCL-NOS), angioimmunoblastic T-cell lymphoma (AITL), anaplastic large cell lymphoma-anaplastic lymphoma kinase positive (ALCL-ALK(+)), and a provisional entity called anaplastic large cell lymphoma-anaplastic lymphoma kinase negative (ALCL-ALK(-)). Because the treatment and prognoses of these neoplasms involve different principles, it is essential to distinguish each one by its clinical, immunophenotypic, genetic, and molecular features. Except for anaplastic large cell lymphoma-anaplastic lymphoma kinase positive, which has no adverse international prognostic index, the prognosis of nodal peripheral T-cell lymphomas is worse than that of aggressive B-cell lymphomas. Chemotherapy based on anthracyclines provides poor outcomes because these neoplasms frequently have multidrug-resistant phenotypes. Based on this, the current tendency is to use intensified cyclophosphamide, doxorubicin, vincristine, prednisolone (CHOP) regimens with the addition of new drugs, and autologous hematopoietic stem cell transplantation. This paper describes the clinical features and diagnostic methods, and proposes a therapeutic algorithm for nodal peripheral T-cell lymphoma patients.

Keywords: Antineoplastic combined chemotherapy protocols; Diseases classification; Immunophenotyping; T-cell Lymphoma; World Health Organization.

Copyright © 2015 Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular. Published by Elsevier Editora Ltda. All rights reserved.

Figures

Figure 1
Figure 1
Morphologic aspects of Peripheral T-cell lymphoma not otherwise specified (PTCL-NOS). (A) Diffuse proliferation of atypical medium sized lymphoid cells. Note some intermingled eosinophils [hematoxylin and eosin (H&E)-stained section]. (B) Diffuse expression of CD3 by the neoplastic lymphoid cells. (C) These cells also express CD4. (D) CD7 antigen is only partially expressed by neoplastic T cells.
Figure 2
Figure 2
Morphologic aspects of angioimmunoblastic T-cell lymphoma. (A) Proliferation of small to medium sized lymphoid cells with mild atypia surrounding prominent high endothelial venules. Occasional large cells are observed, as well as some plasmocytes (H&E-stained section). (B) The majority of neoplastic lymphoid cells express membrane CD3. (C) Neoplastic lymphoid cells also express CD10. (D) CD20 antibody highlights the large B immunoblasts. (E) Follicular dendritic cell meshwork expansion surrounding high endothelial venules is evident with CD21 immunostain.
Figure 3
Figure 3
Morphologic aspects of anaplastic large cell lymphoma-anaplastic lymphoma kinase (ALK) positive. (A) Diffuse proliferation of large, highly atypical cells, with prominent pleomorphism (H&E-stained section). Some hallmark cells can be observed; they present large multilobulated ‘horseshoe-like’ nuclei. Neoplastic cells show diffuse expression of (B) CD30; (C) CD43; (D) epithelial membrane antigens and (E) ALK-1. In this case, ALK-1 positivity present exclusive cytoplasmic pattern.

References

    1. Jaffe E.S., Nicolae A., Pittaluga S. Peripheral T-cell NK-cell lymphomas in the WHO classification: pearls and pitfalls. Mod Pathol. 2013;26(Suppl. 1):71–87.
    1. Jaffe E.S. Pathobiology of peripheral T-cell lymphomas. Hematol Am Soc Hematol Educ Prog. 2006:317–322.
    1. Vose J., Armitage J., Weisenburger D. International peripheral T-cell and natural killer lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 2008;26(25):4124–4130.
    1. Dogan A., Feldman A F. T- and NK-cell lymphoma update. Diagn Histopathol. 2009;16(2):99–110.
    1. Rizvi M.A., Evens A.M., Tallman M.S., Nelson B.P., Rosen S.T. T-cell non-Hodgkin lymphoma. Blood. 2006;107(4):1255–1264.
    1. Tang T., Tay K., Quek R., Tao M., Tan S.Y., Tan L. Peripheral T-cell lymphoma: review and updates of current management strategies. Adv Hematol. 2010;2010:624040.
    1. Leval L., Gisselbrecht C., Gaulard P. Advances in the understanding and management of angioimmunoblastic T-cell lymphoma. Br J Haematol. 2010;148(5):673–689.
    1. Medeiros L.J., Elenitoba-Johnson K.S. Anaplastic large cell lymphoma. Am J Clin Pathol. 2007;127(5):707–722.
    1. Fornari A., Piva R., Chiarle R., Novero D., Inghirami G. Anaplastic large cell lymphoma: one or more entities among T-cell lymphoma. Hematol Oncol. 2009;27(4):161–170.
    1. Ten Berge R.L., Oudejans J.J., Ossenkoppele G.J., Meijer C.J. ALK-negative systemic anaplastic large cell lymphoma: differential diagnostic and prognostic aspects – a review. J Pathol. 2003;200(1):4–15.
    1. Swerdlow S.H., Campo E., Harris N.L., Jaffe E.S., Pileri S.A., Stein H. IARC Press; Lyon: 2008. World Health Organization classification: tumors of hematopoietic and lymphoid tissues.
    1. Attygalle A.D., Kyriakou C., Dupuis J., Grogg K.L., Diss T.C., Wotherspoon A.C. Histologic evolution of angioimmunoblastic T-cell lymphoma in consecutive biopsies: clinical correlation and insights into natural history and disease progression. Am J Surg Pathol. 2007;31(7):1077–1088.
    1. Attygalle A.D., Chuang S.S., Diss T.C., Du M.Q., Isaacson P.G., Dogan A. Distinguishing angioimmunoblastic T-cell lymphoma, unspecified, using morphology, immunophenotype and molecular genetics. Histopathology. 2007;50(4):498–508.
    1. Konstantinou K., Yamamoto K., Ishibashi F., Mizoguchi Y., Kurata M., Nakagawa Y. Angiogenic mediators of the angiopoietin system are highly expressed by CD10-positive lymphoma cells in angioimmunoblastic T-cell lymphoma. Br J Haematol. 2009;144(5):696–704.
    1. Nelson M., Horsman D.E., Weisenburger D.D., Gascoyne R.D., Dave B.J., Loberiza F.R. Cytogenetic abnormalities and clinical correlations in peripheral T-cell lymphoma. Br J Haematol. 2008;141(4):461–469.
    1. Ferreri A.J., Govi S., Pileri S.A., Savage K.J. Anaplastic large cell lymphoma ALK-positive. Crit Rev Oncol Hematol. 2012;83(2):293–302.
    1. Gutiérrez-García G1, García-Herrera A., Cardesa T., Martínez A., Villamor N., Ghita G. Comparison of four prognostic scores in peripheral T-cell lymphoma. Ann Oncol. 2011;22(2):397–404.
    1. López-Guillermo A., Cid J., Salar A., López A., Montalbán C., Castrillo J.M. Peripheral T-cell lymphomas: initial features, natural history, and prognostic factors in a series of 174 patients diagnosed according to the REAL classification. Ann Oncol. 1998;9(8):849–855.
    1. Gallamini A., Stelitano C., Calvi R., Bellei M., Mattei D., Vitolo U. Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. Blood. 2004;103(7):2474–2479.
    1. Went P., Agostinelli C., Gallamini A., Piccaluga P.P., Ascani S., Sabattini E. Marker expression in peripheral T-cell lymphoma: a proposed clinical-pathologic prognostic score. J Clin Orthod. 2006;24(16):2472–2479.
    1. Vose J. International peripheral T-cell lymphoma (PTCL) clinical and pathology review project: poor outcome by prognostic indices and lack of efficacy with anthracyclines. Blood. 2005;106 Abstract 811a.
    1. Armitage J.O. The aggressive peripheral T-cell lymphomas: 2012 update on diagnosis, risk stratification and management. Am J Hematol. 2012;87(5):511–519.
    1. Dearden C.E., Johnson R., Pettengell R., Devereux S., Cwynarski K., Whittaker S. Guidelines for the management of mature T-cell and NK-cell neoplasms (excluding cutaneous T-cell lymphomas) Br J Haematol. 2011;153(4):451–485.
    1. Karakas T., Bergmann L., Stutte H.J., Jäger E., Knuth A., Weidmann E. Peripheral T-cell lymphomas respond well to vincristine, adriamycin, cyclophosphamide, prednisone and etoposide (VACPE) and have a similar outcome as high grade B-cell lymphomas. Leuk Lymphoma. 1996;24(1–2):121–129.
    1. Schmitz N., Trümper L., Ziepert M., Nickelsen M., Ho A.D., Metzner B. Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin's Lymphoma Study Group. Blood. 2010;116(18):3418–3425.
    1. Eyre T.A., Collins G.P. Current treatment and future prospects for peripheral T-cell lymphoma. Drugs Today (Barc) 2013;49(10):631–646.
    1. Yin J., Wei J., Xu J.H., Xiao Y., Zhang Y.C. Autologous stem cell transplantation as the first line treatment for peripheral T-cell lymphoma: results of a comprehensive meta-analysis. Acta Haematol. 2014;131(2):114–125.
    1. d’Amore F., Relander T., Lauritzsen G.F., Jantunen E., Hagberg H., Anderson H. Up front autologous stem cell transplantation in peripheral T-cell lymphoma: NGL-T-01. J Clin Orthod. 2012;30(25):3093–3099.
    1. Yared J., Kimball A. The role of high dose chemotherapy and autologous stem cell transplantation in peripheral T-cell lymphoma: a review of the literature and new perspectives. Cancer Treat Rev. 2013;39(1):51–59.
    1. Savage K.J. Peripheral T-cell Lymphomas. Blood Rev. 2007;21(4):201–216.
    1. Foss F.M. Treatment strategies for peripheral T-cell lymphomas. Best Pract Res Clin Haematol. 2013;26(1):43–56.
    1. Zinzani P.L., Venturini F., Stefoni V., Fina M., Pellegrini C., Derenzini E. Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcome. Ann Oncol. 2010;21(4):860–863.
    1. Bergman A.M., Pinedo H.M., Talianidis I., Veerman G., Loves W.J., van der Wilt C.L. Increased sensivity to gemcitabine of p-glycoproteinand multidrug resistance-associated protein-overexpressing human cancer cell lines. Br J Cancer. 2003;88(12):1963–1970.
    1. Pro B., Advani R., Brice P., Bartlett N.L., Rosenblatt J.D., Illidge T. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Orthod. 2012;30(18):2190–2196.
    1. Friedberg J., Mahadevan D., Jung J., Persky D., Lossos I., Danaee H. Phase II trial of alisertib (MLN8237), an investigational, potent inhibitor of aurora A kinase (AAK), in patients with aggressive B- and T-cell non-Hodgkin lymphoma. ASH Annual Meeting Abstracts, vol. 118; San Diego; 2011. p. 95.
    1. Dearden C.E. Role of single agent analogues in therapy of peripheral T-cell lymphomas. Semin Hematol. 2006;43(2 Suppl. 2):S22–S26.
    1. O’Connor O.A., Pro B., Pinter-Brown L., Bartlett N., Popplewell L., Coiffier B. Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. J Clin Orthod. 2011;29(9):1182–1189.
    1. Marchi E., Bongero D.C., Kalac M., Scotto L., O’Connor O.A. The combination of histone deacetylase inhibitors and hypomethylating agents exhibits marked synergy in preclinical models of T-cell lymphomas. Blood (ASH Annu Meet Abstract) 2013;116(21):3937.
    1. Pierkarz R., Wright J., Frye R., Allen S.L., Joske D., Kirschbaum M. Final results of a phase 2 NCI multicenter study of romidepsin in patients with relapsed peripheral T-cell lymphoma (PTCL) Blood (ASH Annu Meet Abstr) 2009;114(22):1657.
    1. Ansell S.M., Horwitz S.M., Engert A., Khan K.D., Lin T., Strair R. Phase I-II study of an anti-CD30 antibody (MDX-060) in Hodgkin's lymphoma and anaplastic large-cell lymphoma. J Clin Orthod. 2007;25(19):2764–2769.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir